Jonathan R. Strosberg, MD

Articles

Dr. Strosberg on the Need for Additional Targeted Therapies in HCC

January 12th 2021

Jonathan R. Strosberg, MD, discusses the need to develop additional targeted therapies in hepatocellular carcinoma.

Dr. Strosberg on Retreatment With Lutathera in Advanced NETs

October 3rd 2020

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

Dr. Strosberg Discusses Results for KEYNOTE-158

January 21st 2019

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Dr. Strosberg on Radiolabeled Somatostatin Analogs in GEP-NETs

February 12th 2018

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors

May 26th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).

Dr. Strosberg Discusses Trials in Neuroendocrine Tumors

May 16th 2017

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

May 4th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Dr. Strosberg on Future of 177Lu-Dotatate Therapy in Neuroendocrine Tumors

January 24th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the future of using 177Lu-dotatate therapy to treat patients with neuroendocrine tumors.

Dr. Strosberg on Quality of Life Findings for Lu-Dotatate in Patients with Midgut NETs

January 20th 2017

​Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

Dr. Strosberg on Pasireotide for Neuroendocrine Tumors

July 20th 2016

Jonathan R. Strosberg, MD, associate professor at H. Lee Moffitt Cancer Center, discusses pasireotide as a potential treatment for patients with neuroendocrine tumors.

Dr. Strosberg on NETTER-1 Trial Results for Midgut NETs

October 16th 2015

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.